The Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) is set to meet Thursday to vote on whether future COVID-19 shots for the 2026–2027 respiratory season should be updated to target the XFG subvariant. Both outlets report that the panel will consider a monovalent vaccine approach focused on the XFG variant rather than continuing with the current formulation. The discussion is part of the FDA’s process for deciding the composition of upcoming COVID-19 vaccines as virus variants evolve and as seasonal public health needs are assessed. The review is expected to weigh available data related to the variant in question and the implications of changing the vaccine target for the upcoming season. Following the panel’s deliberations and vote, the FDA will decide how to proceed with recommendations for vaccine formulation. The outlets frame the meeting as a targeted decision point for selecting the best match between circulating strains and vaccine design for the 2026–2027 period.